Members Present: Andris Antoniskis, MD; Joshua Bishop, PharmD; Phillip Levine, PhD; Tracy Klein, PhD, FNP; Meena Mital, MD; William Origer, MD; David Pass, MD; Stacy Ramirez, PharmD; James Slater, PharmD; Cathy Zehrung, RPh
Staff Present: Roger Citron, RPh; Megan Herink, PharmD, BCPS; Kathy Ketchum, RPh, MPA:HA; Valerie Smith; Richard Holsapple, RPh; Ralph Magrish, MPA; Amy Burns, PharmD
Staff Present by Phone: Kathy Sentena, PharmD
Audience Present: Jeana Colabianchi (Sunovion); David Barba (Forest); Marcus Shaw (Forest); Roy Palmer (Pfizer); Don Stetcher (Amgen); Aimee Merinar (Amgen); Bruce Howard (Acorda Therapeutics); Kathleen Rogers (Sunovion); Barry Benson (Merck); Dr. Fran Kasier; Kwang Chul Oh (OSU COP); Briana Buckley (Lilly); John Brocars (Lilly); Venus Holder (Lilly); Deborah Wafer (Gilead); Nicholas Berry (BMS); Deron Grothe (Teva); Jan Faiola (Teva); Gwen Morris; Mary Kemhus (Novartis); Shampa De-Oertel (Forest); Rob Pearson (GSK); Mike Donabedian (Vertex); Steve Wright (Boehringer-Ingelheim); James Damm (Pfizer); Roy Palmer (Pfizer)

I. CALL TO ORDER
   a. The meeting was called to order shortly after 1 pm and introductions were made.
   b. Conflict of interest declarations were reviewed; no new conflicts were disclosed.
   c. Minutes from the January 26, 2012 meeting were reviewed and one change noted.
   ACTION: Minutes were approved with recommended change.

II. OLD BUSINESS
   a. Ms. Ketchum brought back decision points from January’s meeting and recommended making ribavirin, telaprevir (Incivek®) and boceprevir (Victrelis®) preferred with the same clinical prior authorization criteria as approved in the January meeting. The Committee asked that the original biopsy recommendation be deferred until staff can consult with a hepatologist.
   ACTION: The Committee approved recommendations with biopsy deferment and added documented adherence to previous dual therapy, prescribed by or in consultation with a specialist, and does not have HIV coinfection to PA criteria. Committee also asked that the hepatologist be consulted regarding the hematologic exclusion criteria.

III. DUR ACTIVITIES
   a. Mr. Magrish presented a legislative update to the Committee.
   b. Mr. Holsapple presented on ProDUR.
   c. Mr. Citron presented on RetroDUR.
   d. Mr. Citron presented the OSU quarterly utilization reports.
   e. Ms. Ketchum presented on PDL evaluation.
   f. Dr. Sentena presented the latest Oregon State Drug Reviews: Atypical Antipsychotic Drug Class Review Summary of Findings and Prophylaxis: Updates and Recommendations.

IV. PRIOR AUTHORIZATION

Agenda items with an asterisk will be discussed by Committee members for the purpose of making recommendations to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 as required by 414.325(9)
a. Dr. Herink presented DUE on Hepatitis B and recommended implementing prior authorization criteria.
   1. Dr. Herink presented new prior authorization criteria for non-preferred Hepatitis B drugs.
   *ACTION*: The Committee approved the criteria as is after Executive Session.
   *ACTION*: The Committee recommended making entecavir non-preferred after Executive Session.

b. Mr. Citron recommended making updates to existing prior authorization criteria.
   1. Erythropoiesis Stimulating Proteins – update guideline notes. Public comment was presented by Claire Mariner from Amgen on Aranesp.
   *ACTION*: The Committee approved the updated criteria and made an ongoing recommendation to update guideline notes as they change. OSU staff will alert HRC of needed updates.
   2. Proton Pump Inhibitors
   *ACTION*: The Committee approved recommended updates.
   3. Topiramate
   *ACTION*: The Committee approved recommended updates after Executive Session.
   4. Hormones – Testosterone (Androgens)
   *ACTION*: The Committee approved recommended updates.
   5. Pulmonary Arterial Hypertension (PAH)
   *ACTION*: The Committee approved recommended updates.

c. Mr. Citron recommended to the Committee updating the early refill threshold from 75% to 80%.
   ACTION: The majority of the Committee approved changing threshold to 80%. Dr. Bishop and Dr. Slater opposed.

V. NEW BUSINESS
a. Dr. Herink presented Neuropathic Pain class update and recommended that topical analgesics are included in current prior authorization criteria to restrict use to patients with postherpetic neuralgia who have failed or cannot tolerate oral therapy with gabapentin and TCAs. Dr. Herink also recommended making gabapentin ER non-preferred, venlafaxine XR capsules preferred and the TCAs (amitriptyline, doxepine, nortriptyline and clomipramine) preferred. Dr. Roy Palmer from Pfizer presented public comment on Pregablin. John Brocarts from Eli Lilly presented public comment on Cymbalta.
   *ACTION*: The Committee approved the recommendations after Executive Session.

b. Dr. Burns presented COPD medications new drug reviews and recommended implementing new prior authorization criteria limiting use of roflumilast to severe or very severe COPD, documented failure of ICS or ICS combination or tiotropium, and currently on a long acting controller medication. Dr. Burns also recommended making roflumilast and indacaterol non-preferred. Shampa De-Oertel from Forest presented public comment on Daliresp. Mary Kemhus from Novartis presented public comment on Arcapta.
   *ACTION*: The Committee approved after Executive Session with recommendation of grandfathering clients currently receiving roflumilast for one year and changing “failed” to “tried” in step 6. The Committee also recommended requiring a previous trial of salmeterol AND formoterol.

   c. Dr. Herink presented drug class scans.
      1. Parkinson’s medications – recommended replacing tolcapone with entacapone, correct PDL to add amantadine as preferred and not perform a full class review at this time.
      *ACTION*: The Committee approved recommendations.
      2. NSAIDs – recommended making Sprix nasal spray non-preferred, add NSAID/PPI combination products to PPI prior authorization criteria and not perform a full class review at this time.
      *ACTION*: The Committee approved recommendations after Executive Session.
      3. Analgesics for Gout – recommended blocking pharmacy claims for pegloticase (paying for through medical benefit) and not perform a full class review at this time.
      *ACTION*: The Committee approved recommendations and recommended colchicine be evaluated for quantity limits.
      4. Alzheimer’s medications - recommended making Aricept 23mg non-preferred, add ProDUR edits to prevent duplicate therapy and not perform a full class review at this time. Jan Faiola from Teva presented public comment on rasagiline.
      *ACTION*: The Committee approved recommendations.

VII. FUTURE BUSINESS
The next meeting will be on March 29, 2012.

Agenda items with an asterisk will be discussed by Committee members for the purpose of making recommendations to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 as required by 414.325(9)
Agenda items with an asterisk will be discussed by Committee members for the purpose of making recommendations to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 as required by 414.325(9)

VIII. ADJOURN
The meeting adjourned at approximately 4:30pm.